Take Care In Promoting Lab-Developed Genetic Tests Or Risk US FDA, FTC Ire
Device-practice attorneys provide tips and precautions for laboratories advertising and promoting non-cleared or unapproved molecular-based diagnostics, and avoiding enforcement.
You may also be interested in...
FDA recently sent untitled letters to three direct-to-consumer genetic testing firms asking them to seek clearance for their making medical claims.
ACLA has recruited Laurence Tribe and Paul Clement, two prominent constitutional legal guns with Supreme Court expertise, to fight FDA over its proposed lab-developed test guidance. The announcement is perhaps the lab industry's most high profile move yet to oppose FDA's plan to regulate lab-developed test services under the device statute with a risk-based phase-in plan.
Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.